Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial

Avihingsanon, AnchaleeAnchaleeAvihingsanonLu, HongzhouHongzhouLuLeong, Chee LoonChee LoonLeongCHIEN-CHING HUNGKoenig, EllenEllenKoenigKiertiburanakul, SasisopinSasisopinKiertiburanakulLee, Man-PoMan-PoLeeSupparatpinyo, KhuanchaiKhuanchaiSupparatpinyoZhang, FujieFujieZhangRahman, SophiaSophiaRahmanD'Antoni, Michelle LMichelle LD'AntoniWang, HongyuanHongyuanWangHindman, Jason TJason THindmanMartin, HalHalMartinBaeten, Jared MJared MBaetenLi, TaishengTaishengLi2023-12-112023-12-112023-1023523018https://scholars.lib.ntu.edu.tw/handle/123456789/637655For most adults with HIV-1 and hepatitis B virus (HBV) coinfection, initial recommended treatment is a tenofovir-containing antiretroviral regimen, but no randomised studies have compared tenofovir disoproxil fumarate with tenofovir alafenamide. We aimed to investigate whether bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for viral suppression in individuals with HIV-1 and HBV coinfection at 48 and 96 weeks.en[SDGs]SDG3Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trialjournal article10.1016/S2352-3018(23)00151-0374949422-s2.0-85169916784https://api.elsevier.com/content/abstract/scopus_id/85169916784